Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.38 |
| ▸ | KMT5B | Q4FZB7 | 2/20 | 0.34 |
| ▸ | KMT5C | Q86Y97 | 2/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 7/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17119701 | 0.95 | KMT2A (0.44) | MEN1KMT2ACSNK2BKMT5BKMT5C | |
| SCHEMBL17119633 | 0.94 | KMT2A (0.46) | MEN1KMT2ACSNK2BKMT5BKMT5C | |
| SCHEMBL23335275 | 0.93 | ERN1 (0.39) | CSNK2BERN1PIM1 | |
| SCHEMBL23335575 | 0.92 | KMT2A (0.49) | MEN1KMT2ACSNK2BKMT5BKMT5C | |
| SCHEMBL23335274 | 0.90 | BPTF (0.38) | MEN1KMT2AMAPK1 | |
| SCHEMBL17119636 | 0.87 | KAT2B (0.50) | KAT2BERN1 | |
| SCHEMBL24950011 | 0.85 | MEN1 (0.37) | MEN1KMT2ACSNK2BKMT5BKMT5C | |
| SCHEMBL23335574 | 0.85 | MEN1 (0.37) | MEN1KMT2ACSNK2BKMT5BKMT5C | |
| SCHEMBL24950187 | 0.84 | BPTF (0.47) | — | |
| SCHEMBL24949759 | 0.84 | BPTF (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315869-A1 | COMPOUNDS AND METHODS FOR CSK MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2021-10-14 | — | — | US | disclosed |
| US-20210315869-A1 | COMPOUNDS AND METHODS FOR CSK MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2021-10-14 | — | — | US | disclosed |
| WO-2021202900-A1 | 1,6-NAPHTHYRIDINE COMPOUNDS AND METHODS FOR CSK MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315869-A1 | COMPOUNDS AND METHODS FOR CSK MODULATION AND INDICATIONS THEREFOR | MC2R, SLC10A1, SLC10A2 | MEN1 435/4885KMT2A 3938/4885CSNK2B 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.